近畿大学ライフサイエンス研究所Kindai University Life Science Research Institute

令和6年度

巻頭言

2024年度
ライフサイエンス研究所紀要発刊によせて
研究所長
岡田　斉（生化学教室教授）

　近畿大学ライフサイエンス研究所は、1974 年に大阪狭山キャンパスに設立されて以
来、生命現象の科学的解明と人類の健康及び福祉の増進に貢献してまいりました。先進
的な分析技術、特にゲノムの網羅的解析を基盤とした個別化医療とプレシジョン医療の
推進は、当研究所の重要な柱です。
　2022 年には、難治性神経疾患の診断法・治療法開発を目指す新たな研究室を設置し、
革新的な治療法の研究に邁進しております。また、研究成果の社会実装に向けて、複数
の共同研究プロジェクトを積極的に展開し、連携を強化してまいりました。
　一方で、我が国全体として研究力低下、大学医学部における研究者や若い医師の不足、
若手研究者の研究時間の確保といった課題に直面しているのも事実です。医師の働き方
改革や研究資源の効率的な活用が求められる中、持続可能な研究環境の構築は喫緊の課
題です。
　こうした現状を踏まえ、当研究所では柔軟な働き方を支援、所内外の交流を促進する
など、多様な取り組みを推進しています。厳しい環境下にもかかわらず、2024 年度は基
礎・臨床の両面で、数多くの質の高い研究成果が発表されました。これは、日々研究に
真摯に取り組む研究者および技術職員の皆さんの弛まぬ努力の賜物であり、心より敬意
を表します。
　今後は、ゲノム解析を含む多層的なオミックス解析を統合的に進め、データ駆動型研
究を推進するとともに、最先端の画像解析技術の導入を通じて、より深く生命現象に迫
る研究を推進してまいります。ライフサイエンス研究所は所員一丸となって、生命科学
の発展と社会貢献に向け、不断の努力を続けてまいります。
　日頃より当研究所の研究活動を支えてくださる全ての関係者の皆様に、心より感謝申
し上げます。

令和6年度ライフサイエンス研究所紀要 研究業績

岡田 斉 （ライフサイエンス研究所所長 兼任 近畿大学 医学部 生化学教室 主任教授）

  1. Dash S, Ueda T, Komuro A, Honda M, Sugisawa R, Okada H. Correction: Deoxycytidine kinase
    inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference
    in pancreatic cancer Cell Death Dis. 2024 May 31;15(5):384. doi: 10.1038/s41419-024-06628-3.
  2. Honda M, Inoue R, Nishiyana K, Ueda T, Komuro A, Amano H, Sugisawa R, Dashi S, Shirakawa
    J, Okada H. Vgll2 as an integrative regulator of mitochondrial function and contractility specific to
    skeletal muscle J Cell Phisiol. 2024 Dec; 239(12):e31436. Doi: 10.1002/jcp.31436. epub 2024 Sep
    17.

永井 義隆（ライフサイエンス研究所 副所長 兼任 近畿大学 医学部 内科学教室〔脳神経内科部門〕 主任教授）

  1. Terayama A., Kuwahara M., Yoshikawa K., Yamagishi Y., Samukawa M., Yamashita S., Onishi K.,
    Nagano T., Tatsumi C., Ishii J., Kawamoto M., Tokashiki T., Deguchi S., Deguchi K., Ishida A., Baba
    Y., Yamaguchi S., Kusunoki S., Nagai Y. Takotsubo cardiomyopathy in Guillain-Barré syndrome. J.
    Neurol. 271(7): 4067-4074 (2024) doi: 10.1007/s00415-024-12295-3
  2. Kojita Y., Kono A., Yamada T., Yamada M., Im S.-W., Kozuka T., Kaida H., Kuwahara M., Nagai
    Y., Ishii K. Differentiating multiple sclerosis and neuromyelitis optica spectrum disorder through
    pontine trigeminal nerve lesions: a comparative MRI study. Eur. J. Radiol 178: 111597 (2024) doi:
    10.1016/j.ejrad.2024.111597.
  3. Kamano S., Ozawa D., Ikenaka K., *Nagai Y. Role of Lipids in the pathogenesis of Parkinson's
    disease. Int. J. Mol. Sc৻. 25(16): 8935 (2024) doi: 10.3390/ijms25168935
  4. Kojita Y., Kono A., Yamada T., Yamada M., Im S.-W., Kozuka T., Kaida H., Kuwahara M., Nagai
    Y., Ishii K. Neuromyelitis optica spectrum disorder mimicking cerebral autosomal dominant
    arteriopathy with subcortical infarcts and leukoencephalopathy with symmetrical lesions in the
    temporal poles and external capsules on MRI. Neuroradiol. 66(11): 1887-1891 (2024) doi:
    10.1007/s00234-024-03458-0.
  5. Ishihara T., Tada M., Kanemitsu Y., Takahashi Y., Ishikawa K., Ikenaka K., Hirano M., Yokota T.,
    Minakawa E.N., Saito K., Nagai Y., Onodera O. L-arginine in patients with spinocerebellar ataxia type
    6: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. eClinicalMedicine 78:
    102952 (2024) doi.org/10.1016/j.eclinm.2024.102952
  6. Revankar G.S., Ozono T., Suzuki M., Kanemoto H., Furuya K., Shigenobu K., Yoshiyama K.,
    Yamamoto Y., Ogasawara I., Yoshida N., Iwasaki S., Saeki C., Nishio Y., Nakatani D., Asai K.,
    Kajiyama Y., Shimizu M., Hayashi T., Taniguchi S., Suzuki Y., Inada R., Taminato T., Nagai Y.,
    Hashimoto M., Ikeda M., Mori E., Mochizuki H., Nakata K. Perceptual constancy of pareidolias across
    paper and digital testing formats in neurodegenerative diseases. Heliyon 10(22): e40254 (2024) doi:10.1016/j.heliyon.2024.e40254.
  7. Miwa T., Takeuchi E., Ogawa K., Abdelhamid R.F., Morita J., Hiraki Y., Yamasaki Y., Nakamura
    Y., Ohkura N., Saito Y., Murayama S., Nagai Y., Mochizuki H., Nagano S. Alternative splicing
    alterations in patients with amyotrophic lateral sclerosis: Link to the disruption of TDP-43 functions.
    Neurol. Clin. Neurosci. 13: 187–194 (2025) doi: 10.1111/ncn3.12880
  8. Jinno J., Abdelhamid R.F., Morita J., Saga R., Yamasaki Y., Kadowaki A., Ogawa K., Kimura Y.,
    Ikenaka K., Beck G., Baba K., Nagai Y., Kasahara E., Sekiyama A., Hirayama T., Hozumi I., Hasegawa T., Araki T., Mochizuki H., Nagano S. TDP-43 transports ferritin heavy chain mRNA to regulate oxidative stress in neuronal axons. Neurochem. Int. 184: 105934 (2025) doi:
    10.1016/j.neuint.2025.105934
  9. Danno D., Tada H., Oda I., Kawashita N., Hirano M., Kitamura S., Kikui S., Samukawa M.,
    Yoshikawa K., Mitsui Y., Nagai Y., Takeshima T., Saigoh K. Expanding the genetic and clinical
    spectrum of SCN1A-related hemiplegic migraine: analysis of mutations in Japanese. Int. J. Mol. Sc৻.
    26(4): 1426 (2025) doi: 10.3390/ijms26041426
  10. Fujii S., Yaguchi H., Kudo A., Eguchi K., Nomura T., Hamada Y., Hirai A., Fukumoto Y.,
    Yamagishi Y., Yoneda M., Tanaka K., Kimura A., Tsuzaka K., Nagai Y., Yabe I. Autoimmune cerebellar ataxia with Kelch-like protein 11 antibodies in a large cohort study. J. Neurol. 272(4):282 (2025) doi:10.1007/s00415-025-13033-z
  11. Hasumi M., Ito H., Machida K., Niwa T., Taminato T., Nagai Y., Imataka H., Taguchi H. Dissecting
    the mechanism of NOP56 GGCCUG repeat-associated non-AUG translation using cell-free
    translation systems. J. Biol. Chem. (in press) doi: 10.1016/j.jbc.2025.108360
  12. Minakawa EN, Owari K, Nogami N, Nakatani T, Koizumi M, Kawanobe A, Saga Y, Kudo M,
    Noguchi S, Hanakawa T, Hori Y, Numazawa H, Takeuchi T, Katakai Y, Saito R, Nagai Y, Saito Y,
    Tomioka I, Seki K. Establishment of a second-generation transgenic marmoset model of
    polyglutamine disease recapitulating neurological symptoms and pathology. bioRxiv. 2025 Mar. doi:
    10.1101/2025.03.12.642922.

重吉 康史（ライフサイエンス研究所 教授 兼任 近畿大学 医学部 解剖学教室 主任教授）

  1. Kanazawa Y, Takahashi T, Inoue T, Nagano M, Koinuma S, Eiyo H, Tamura Y, Miyachi R, Iida N,
    Miyahara K, Shigeyoshi Y. Effects of Aging on Intramuscular Collagen-Related Factors After Injury
    to Mouse Tibialis Anterior Muscle. Int J Mol Sci. 2025 Jan 18;26(2):801.doi:10.3390/ijms26020801.
  2. Miyawaki Y, Nishida A, Fukushima K, Matsumoto A, Hamano T, Mori Y, Nagano M, Tokuda
    IT, Shigeyoshi Y, Node K, Akashi M. Chronic circadian misalignment is a risk factor for hair growth
    impairment. iScience. 2024 Sep 18;27(10):110974. doi: 10.1016/j.isci.2024
  3. Yoshikawa T, Honma KI, Shigeyoshi Y, Yamagata Y, Honma S.A critical role of Ca2+/calmodulindependent protein kinase II in coupling between evening and morning circadian oscillators in the suprachiasmatic nucleus. Eur J Neurosci. 2024 Jul;60(2):3828-3842. doi: 10.1111/ejn.16316

西尾 和人（ライフサイエンス研究所 ゲノムセンター長 教授 兼任 近畿大学 医学部 ゲノム生物学教室 主任教授）

  1. Fujita Y, Matsuoka H, Chiba Y, Tsurutani J, Yoshida T, Sakai K, Nakura M, Sakamoto R, Makimura C,Ohtake Y, Tanaka K, Hayashi H, Takahama T, Tanizaki J, Koyama A, Nishio K, Nakagawa K. Dual
    single‑nucleotide polymorphism biomarker combination for opioid selection to treat cancer pain. Mol
    Clin Oncol. 2024 Nov 29;22(2):14. doi: 10.3892/mco.2024.2809. eCollection 2025 Feb.
  2. Nagayama A, Miyagawa C, Kashima Y, Ohta M, Otani T, Kurosaki T, Isomoto K, Inagaki C, Takahama T, Yonesaka K, Hayashi H, Sakai K, Nishio K, Nakagawa K, Matsumura N. Malignant transformation of an ovarian mature teratoma diagnosed 17 years ago: a case report and literature review of treatment with immune checkpoint inhibitors. Int Cancer Conf J. 2024 Dec 19;14(2):85-90. doi: 10.1007/s13691-024-00740-z. eCollection 2025 Apr.
  3. Yonesaka K, Kurosaki T, Tanizaki J, Kawakami H, Tanaka K, Maenishi O, Takamura S, Sakai K, Chiba Y, Teramura T, Goto H, Otsuka E, Okida H, Funabashi M, Hashimoto Y, Hirotani K, Kamai Y, Kagari T, Nishio K, Kakimi K, Hayashi H. Chromosomal Instability Is Associated with cGAS-STING Activation in EGFR-TKI Refractory Non-Small-Cell Lung Cancer. Cells. 2025 Mar 17;14(6):447. doi:
    10.3390/cells14060447.
  4. Aoki T, Nishida N, Kurebayashi Y, Sakai K, Fujiwara N, Tsurusaki M, Hanaoka K, Morita M, Chishina H, Takita M, Hagiwara S, Ida H, Ueshima K, Minami Y, Takebe A, Murase T, Kamei K, Nakai T, Matsumoto I, Nishio K, Kudo M. Molecular Classification of Hepatocellular Carcinoma based on Zoned Metabolic Feature and Oncogenic Signaling Pathway. Clin Mol Hepatol. 2025 Mar 11. doi:
    10.3350/cmh.2024.1088. Online ahead of print.
  5. Shiraishi N, Takahama T, Sakai K, Tanaka K, Nakagawa Y, Kanemura H, Nakayama T, Kawanaka
    Y, Kurosaki T, Suzuki S, Iwasa T, Tanizaki J, Inagaki C, Yonesaka K, Fukuoka K, Mitsudomi T, Nishio K, Hayashi H, Nakagawa K. Detection of Overlooked Rare EGFR Mutations in Non-small Cell Lung Cancer Using Multigene Testing. Thorac Cancer. 2025 Feb;16(3):e70007. doi: 10.1111/1759-7714.70007.
  6. Kaneda H, Daga H, Okada A, Nakatani Y, Tani Y, Oka T, Sawa K, Sakai K, Nishio K, Kawaguchi
    T. Efficacy of ramucirumab combined with erlotinib or osimertinib in untreated EGFR-mutated NSCLC patients with asymptomatic brain metastases: insights from molecular biomarkers in the RELAY-brain trial. Invest New Drugs. 2025 Feb;43(1):147-156. doi: 10.1007/s10637-025-01505-y. Epub 2025 Jan 23.
  7. Kenmotsu H, Sakai K, Mori K, Kato T, Sugawara S, Kirita K, Yoneshima Y, Azuma K, Nishino K,
    Teraoka S, Koyama R, Masuda K, Hayashi H, Toyozawa R, Miura S, Sato Y, Nakagawa K, Yamamoto N, Nishio K, Takahashi T. Final Analysis Data and Exploratory Biomarker Analysis of a Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib Monotherapy for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: The WJOG9717L Study. JTO Clin Res Rep. 2024 Aug 23;5(11):100716. doi: 10.1016/j.jtocrr.2024.100716. eCollection 2024 Nov.
  8. Hata A, Katakami N, Takase N, Kibata K, Yamanaka Y, Tamiya M, Mori M, Kijima T, Morita S, Sakai K, Nishio K. Afatinib plus bevacizumab combination after osimertinib resistance in advanced EGFRmutant non-small cell lung cancer: Phase II ABCD-study. Lung Cancer. 2024 Nov;197:107988. doi: 10.1016/j.lungcan.2024.107988. Epub 2024 Oct 5.
  9. Sakai K, Ohara S, Tanaka J, Suda K, Muramatsu T, Uematsu C, Tsutani Y, Mitsudomi T, Nishio K.
    Improved platelet separation performance from whole blood using an acoustic fluidics system. Cancer Sci. 2024 Nov;115(11):3795-3803. doi: 10.1111/cas.16337. Epub 2024 Sep 22.
  10. De Velasco MA, Sakai K, Mitani S, Kura Y, Minamoto S, Haeno T, Hayashi H, Nishio K. A machine
    learning-based method for feature reduction of methylation data for the classification of cancer tissue origin. Int J Clin Oncol. 2024 Dec;29(12):1795-1810. doi: 10.1007/s10147-024-02617-w. Epub 2024 Sep 18.
  11. Nagatani Y, Kiyota N, Imamura Y, Koyama T, Funakoshi Y, Komatsu M, Itoh T, Teshima M, Nibu KI, Sakai K, Nishio K, Shimomura M, Nakatsura T, Ikarashi D, Nakayama T, Kitano S, Minami H. Different characteristics of the tumor immune microenvironment among subtypes of salivary gland cancer. Asia Pac J Clin Oncol. 2024 Dec;20(6):779-788. doi: 10.1111/ajco.14108. Epub 2024 Sep 4.
  12. Kura Y, De Velasco MA, Sakai K, Uemura H, Fujita K, Nishio K. Exploring the relationship between ulcerative colitis, colorectal cancer, and prostate cancer. Hum Cell. 2024 Nov;37(6):1706-1718. doi: 10.1007/s13577-024-01118-2. Epub 2024 Aug 20.
  13. Wakamori C, De Velasco MA, Sakai K, Kura Y, Matsushita M, Fujimoto S, Hatano K, Nonomura N,
    Fujita K, Nishio K, Uemura H. A cross-species analysis of fecal microbiomes in humans and mice reveals similarities and dissimilarities associated with prostate cancer risk. Prostate. 2024 Nov;84(15):1375-1386.doi: 10.1002/pros.24776. Epub 2024 Aug 7.
  14. Aoki T, Nishida N, Kurebayashi Y, Sakai K, Morita M, Chishina H, Takita M, Hagiwara S, Ida H,
    Ueshima K, Minami Y, Tsurusaki M, Nakai T, Sakamoto M, Nishio K, Kudo M. Two Distinct
    Characteristics of Immune Microenvironment in Human Hepatocellular Carcinoma with Wnt/β-Catenin Mutations. Liver cancer. 2023 Oct 9;13(3):285-305. doi: 10.1159/000533818. eCollection 2024 Jun.
  15. Kanemura H, Yokoyama T, Nakajima R, Nakamura A, Kuroda H, Kitamura Y, Shoda H, Mamesaya
    N, Miyata Y, Okamoto T, Okishio K, Oki M, Sakairi Y, Chen-Yoshikawa TF, Aoki T, Ohira T, Matsumoto I, Ueno K, Miyazaki T, Matsuguma H, Yokouchi H, Otani T, Ito A, Sakai K, Chiba Y, Nishio K, Yamamoto N, Okamoto I, Nakagawa K, Takeda M. The Tumor Immune Microenvironment Is Associated With Recurrence in Early-Stage Lung Adenocarcinoma. JTO Clin Res Rep. 2024 Mar 8;5(4):100658. doi:10.1016/j.jtocrr.2024.100658. eCollection 2024 Apr.
  16. Hayashi H, Chamoto K, Hatae R, Kurosaki T, Togashi Y, Fukuoka K, Goto M, Chiba Y, Tomida S,
    Ota T, Haratani K, Takahama T, Tanizaki J, Yoshida T, Iwasa T, Tanaka K, Takeda M, Hirano T, Yoshida H, Ozasa H, Sakamori Y, Sakai K, Higuchi K, Uga H, Suminaka C, Hirai T, Nishio K, Nakagawa K, Honjo T. Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade. J Clin Invest. 2024 Apr 1;134(7):e168318. doi: 10.1172/JCI168318.

坂井 和子（ライフサイエンス研究所ゲノムセンター 講師 兼任 近畿大学 医学部 ゲノム生物学教室 講師）

  1. Nagayama A, Miyagawa C, Kashima Y, Ohta M, Otani T, Kurosaki T, Isomoto K, Inagaki C, Takahama T, Yonesaka K, Hayashi H, Sakai K, Nishio K, Nakagawa K, Matsumura N. Malignant transformation of an ovarian mature teratoma diagnosed 17 years ago: a case report and literature review of treatment with immune checkpoint inhibitors. Int Cancer Conf J. 2024 Dec 19;14(2):85-90. doi: 10.1007/s13691-024-00740-z. eCollection 2025 Apr.
  2. Yonesaka K, Kurosaki T, Tanizaki J, Kawakami H, Tanaka K, Maenishi O, Takamura S, Sakai K, Chiba Y, Teramura T, Goto H, Otsuka E, Okida H, Funabashi M, Hashimoto Y, Hirotani K, Kamai Y, Kagari T, Nishio K, Kakimi K, Hayashi H. Chromosomal Instability Is Associated with cGAS-STING Activation in EGFR-TKI Refractory Non-Small-Cell Lung Cancer. Cells. 2025 Mar 17;14(6):447. doi:
    10.3390/cells14060447.
  3. Aoki T, Nishida N, Kurebayashi Y, Sakai K, Fujiwara N, Tsurusaki M, Hanaoka K, Morita M, Chishina H, Takita M, Hagiwara S, Ida H, Ueshima K, Minami Y, Takebe A, Murase T, Kamei K, Nakai T, Matsumoto I, Nishio K, Kudo M. Molecular Classification of Hepatocellular Carcinoma based on Zoned Metabolic Feature and Oncogenic Signaling Pathway. Clin Mol Hepatol. 2025 Mar 11. doi:
    10.3350/cmh.2024.1088. Online ahead of print.
  4. Shiraishi N, Takahama T, Sakai K, Tanaka K, Nakagawa Y, Kanemura H, Nakayama T, Kawanaka Y, Kurosaki T, Suzuki S, Iwasa T, Tanizaki J, Inagaki C, Yonesaka K, Fukuoka K, Mitsudomi T, Nishio K, Hayashi H, Nakagawa K. Detection of Overlooked Rare EGFR Mutations in Non-small Cell Lung Cancer Using Multigene Testing. Thorac Cancer. 2025 Feb;16(3):e70007. doi: 10.1111/1759-7714.70007.
  5. Kaneda H, Daga H, Okada A, Nakatani Y, Tani Y, Oka T, Sawa K, Sakai K, Nishio K, Kawaguchi T.
    Efficacy of ramucirumab combined with erlotinib or osimertinib in untreated EGFR-mutated NSCLC
    patients with asymptomatic brain metastases: insights from molecular biomarkers in the RELAY-brain trial. Invest New Drugs. 2025 Feb;43(1):147-156. doi: 10.1007/s10637-025-01505-y. Epub 2025 Jan 23.
  6. Kenmotsu H, Sakai K, Mori K, Kato T, Sugawara S, Kirita K, Yoneshima Y, Azuma K, Nishino K,
    Teraoka S, Koyama R, Masuda K, Hayashi H, Toyozawa R, Miura S, Sato Y, Nakagawa K, Yamamoto N, Nishio K, Takahashi T. Final Analysis Data and Exploratory Biomarker Analysis of a Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib Monotherapy for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: The WJOG9717L Study. JTO Clin Res Rep. 2024 Aug 23;5(11):100716. doi: 10.1016/j.jtocrr.2024.100716. eCollection 2024 Nov.
  7. Hata A, Katakami N, Takase N, Kibata K, Yamanaka Y, Tamiya M, Mori M, Kijima T, Morita S, Sakai K, Nishio K. Afatinib plus bevacizumab combination after osimertinib resistance in advanced EGFRmutant non-small cell lung cancer: Phase II ABCD-study. Lung Cancer. 2024 Nov;197:107988. doi:10.1016/j.lungcan.2024.107988. Epub 2024 Oct 5.
  8. Sakai K, Ohara S, Tanaka J, Suda K, Muramatsu T, Uematsu C, Tsutani Y, Mitsudomi T, Nishio K.
    Improved platelet separation performance from whole blood using an acoustic fluidics system. Cancer Sci. 2024 Nov;115(11):3795-3803. doi: 10.1111/cas.16337. Epub 2024 Sep 22.
  9. De Velasco MA, Sakai K, Mitani S, Kura Y, Minamoto S, Haeno T, Hayashi H, Nishio K. A machine
    learning-based method for feature reduction of methylation data for the classification of cancer tissue origin. Int J Clin Oncol. 2024 Dec;29(12):1795-1810. doi: 10.1007/s10147-024-02617-w. Epub 2024 Sep 18.
  10. Nagatani Y, Kiyota N, Imamura Y, Koyama T, Funakoshi Y, Komatsu M, Itoh T, Teshima M, Nibu KI, Sakai K, Nishio K, Shimomura M, Nakatsura T, Ikarashi D, Nakayama T, Kitano S, Minami H. Different characteristics of the tumor immune microenvironment among subtypes of salivary gland cancer. Asia Pac J Clin Oncol. 2024 Dec;20(6):779-788. doi: 10.1111/ajco.14108. Epub 2024 Sep 4.
  11. Kura Y, De Velasco MA, Sakai K, Uemura H, Fujita K, Nishio K. Exploring the relationship between ulcerative colitis, colorectal cancer, and prostate cancer. Hum Cell. 2024 Nov;37(6):1706-1718. doi:10.1007/s13577-024-01118-2. Epub 2024 Aug 20.
  12. Wakamori C, De Velasco MA, Sakai K, Kura Y, Matsushita M, Fujimoto S, Hatano K, Nonomura N,
    Fujita K, Nishio K, Uemura H. A cross-species analysis of fecal microbiomes in humans and mice reveals similarities and dissimilarities associated with prostate cancer risk. Prostate. 2024 Nov;84(15):1375-1386. doi: 10.1002/pros.24776. Epub 2024 Aug 7.
  13. Aoki T, Nishida N, Kurebayashi Y, Sakai K, Morita M, Chishina H, Takita M, Hagiwara S, Ida H,
    Ueshima K, Minami Y, Tsurusaki M, Nakai T, Sakamoto M, Nishio K, Kudo M. Two Distinct
    Characteristics of Immune Microenvironment in Human Hepatocellular Carcinoma with Wnt/β-Catenin Mutations. Liver cancer. 2023 Oct 9;13(3):285-305. doi: 10.1159/000533818. eCollection 2024 Jun.
  14. Kanemura H, Yokoyama T, Nakajima R, Nakamura A, Kuroda H, Kitamura Y, Shoda H, Mamesaya
    N, Miyata Y, Okamoto T, Okishio K, Oki M, Sakairi Y, Chen-Yoshikawa TF, Aoki T, Ohira T, Matsumoto I, Ueno K, Miyazaki T, Matsuguma H, Yokouchi H, Otani T, Ito A, Sakai K, Chiba Y, Nishio K, Yamamoto N, Okamoto I, Nakagawa K, Takeda M. The Tumor Immune Microenvironment Is Associated With Recurrence in Early-Stage Lung Adenocarcinoma. JTO Clin Res Rep. 2024 Mar 8;5(4):100658. doi:10.1016/j.jtocrr.2024.100658. eCollection 2024 Apr.
  15. Hayashi H, Chamoto K, Hatae R, Kurosaki T, Togashi Y, Fukuoka K, Goto M, Chiba Y, Tomida S,
    Ota T, Haratani K, Takahama T, Tanizaki J, Yoshida T, Iwasa T, Tanaka K, Takeda M, Hirano T, Yoshida H, Ozasa H, Sakamori Y, Sakai K, Higuchi K, Uga H, Suminaka C, Hirai T, Nishio K, Nakagawa K, Honjo T. Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade. J Clin Invest. 2024 Apr 1;134(7):e168318.doi:10.1172/JCI168318.

武内 敏秀（ライフサイエンス研究所 准教授）

  1. Takakura Y, Hanayama R, Akiyoshi K, Futaki S, Hida K, Ichiki T, Ishii-Watabe A, Kuroda M,
    Maki K, Miura Y, Okada Y, Seo N, Takeuchi T, Yamaguchi T, Yoshioka Y. Quality and Safety
    Considerations for Therapeutic Products Based on Extracellular Vesicles. Pharm Res. 2024
    Aug;41(8):1573-1594. doi: 10.1007/s11095-024-03757-4.
  2. Minakawa EN, Owari K, Nogami N, Nakatani T, Koizumi M, Kawanobe A, Saga Y, Kudo M,
    Noguchi S, Hanakawa T, Hori Y, Numazawa H, Takeuchi T, Katakai Y, Saito R, Nagai Y, Saito Y,
    Tomioka I, Seki K. Establishment of a second-generation transgenic marmoset model of
    polyglutamine disease recapitulating neurological symptoms and pathology. bioRxiv. 2025 Mar. doi:
    10.1101/2025.03.12.642922.

archive

近畿大学
近畿大学医学部

Copyright (C) Kindai University Life Science Research Institute All rights reserved.